Role of Systemic Therapy in TACE-Eligible Patients
The panelist discusses how for patients initially eligible for embolization, systemic therapy may be combined with transarterial chemoembolization (TACE) upfront for high-risk disease (ie, large tumor burden, elevated AFP) or reserved for progression after regional therapy in lower-risk cases. Treatment decisions should be individualized based on tumor characteristics, liver function, and patient preferences.
Video content above is prompted by the following:
- What are your perspectives on when and how systemic therapy fits into the treatment paradigm for patients who are initially eligible for embolization?
- Should systemic therapy be considered upfront in combination with eg, TACE or reserved for progression after regional therapy?
- Review and discuss recent evidence from the EMERALD-1 and LEAP-012 trials.
- What are the clinical implications of these data?
- What patient/nonpatient specific factors would influence these treatment decisions?
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
